|
|
Home  FAQ's CellRenew FAQ
|
CellRenew FAQ |
|
|
|
Page 3 of 9
What do the studies show?
The
results of a recent double-blind, placebo controlled, clinical trial
has proved the benefits of Collagen Type II for treating the symptoms
of pain and immobility associated with arthritis. Drs. K. Buckman and
J. Gutierrez report an 89.9% positive response rate, within 45 days,
for the participants who consumed at least 2000 mg of Collagen Type II
per day. To review the results of this report, click here.
Back
in 1958, a Dr. John Prudden, former professor of surgery at the College
of Physicians and Surgeons of Columbia University, discovered that
cartilage dramatically accelerated wound healing after he applied it as
a topical agent. He later discovered the anti-inflammatory properties
after applying it to a chronic ulcer a patient had on his skin. In the
mid-sixties Dr. Prudden joined with Dr. John Allen to conduct a study
of non-healing wounds and the use of Collagen Type II-rich cartilage.
The result was a 42% improvement between the treated wounds and the
control wounds. This difference was considered highly significant.
Then, Dr. Prudden reported having successfully treated more than 50
patients, starting in 1974, with osteoarthritis, rheumatoid arthritis,
psoriasis and many other ailments.
In 1968, Dr. A.J. Bollet's
research showed that the Collagen Type II-rich cartilage promoted
protein and chondroitin sulfate synthesis, key components in the bodies
construction of cartilage. Of the different types of cartilage tested,
the one with the highest level of Collagen Type II, anti-inflammatory
proteoglycans (the healing properties) was chicken sternal cartilage.
CellRenew is 100% chicken sternal cartilage.
|
|
Your Account
Welcome, guest.
|
